Neurocrine Biosciences Stock Performance
| NBIX Stock | USD 115.60 3.68 3.29% |
The company secures a Beta (Market Risk) of 0.68, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, Neurocrine Biosciences' returns are expected to increase less than the market. However, during the bear market, the loss of holding Neurocrine Biosciences is expected to be smaller as well. At this point, Neurocrine Biosciences has a negative expected return of -0.24%. Please make sure to verify Neurocrine Biosciences' maximum drawdown and rate of daily change , to decide if Neurocrine Biosciences performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Neurocrine Biosciences has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of inconsistent performance in the last few months, the Stock's forward indicators remain fairly strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Actual Historical Performance (%)
One Day Return 3.29 | Five Day Return 5.22 | Year To Date Return (16.15) | Ten Year Return 217.84 | All Time Return 824.8 |
Ex Dividend Date 1995-12-29 |
1 | Disposition of 272 shares by Ingrid Delaet of Neurocrine Biosciences at 138.1 subject to Rule 16b-3 | 12/31/2024 |
2 | Disposition of 60188 shares by Kyle Gano of Neurocrine Biosciences at 32.99 subject to Rule 16b-3 | 01/15/2025 |
3 | Neurocrine Q4 Earnings on the Horizon Analysts Insights on Key Performance Measures | 02/04/2025 |
4 | Neurocrine Among Top Insider Stock Buys And Sells In January | 02/18/2025 |
5 | Disposition of 1098 shares by Eric Benevich of Neurocrine Biosciences at 116.7421 subject to Rule 16b-3 | 02/26/2025 |
6 | GWK Investment Management LLC Grows Holdings in Neurocrine Biosciences, Inc. | 02/28/2025 |
7 | Neurocrine Biosciences Initiates Phase 1 Clinical Study for New VMAT2 Inhibitor | 03/05/2025 |
8 | Disposition of 1352 shares by Abernethy Matt of Neurocrine Biosciences at 116.8487 subject to Rule 16b-3 | 03/06/2025 |
9 | Voyager Reports Fourth Quarter and Full Year 2024 Financial and Operating Results | 03/11/2025 |
10 | aTyr Pharma Announces Fourth Quarter and Full Year 2024 Results and Provides Corporate Update | 03/13/2025 |
11 | Acquisition by Roberts Eiry of 1860 shares of Neurocrine Biosciences subject to Rule 16b-3 | 03/14/2025 |
12 | Primecap Management Co. CA Sells 10,290 Shares of Neurocrine Biosciences, Inc. | 03/19/2025 |
13 | Neurocrine Biosciences Inc Reports Promising 48-Week Remission Data for Tardive ... | 03/21/2025 |
| Begin Period Cash Flow | 259.1 M |
Neurocrine |
Neurocrine Biosciences Relative Risk vs. Return Landscape
If you would invest 13,653 in Neurocrine Biosciences on December 24, 2024 and sell it today you would lose (2,166) from holding Neurocrine Biosciences or give up 15.86% of portfolio value over 90 days. Neurocrine Biosciences is currently does not generate positive expected returns and assumes 2.8208% risk (volatility on return distribution) over the 90 days horizon. In different words, 25% of stocks are less volatile than Neurocrine, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Neurocrine Biosciences Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Neurocrine Biosciences' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Neurocrine Biosciences, and traders can use it to determine the average amount a Neurocrine Biosciences' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.085
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | NBIX |
Estimated Market Risk
| 2.82 actual daily | 25 75% of assets are more volatile |
Expected Return
| -0.24 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.08 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Neurocrine Biosciences is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Neurocrine Biosciences by adding Neurocrine Biosciences to a well-diversified portfolio.
Neurocrine Biosciences Fundamentals Growth
Neurocrine Stock prices reflect investors' perceptions of the future prospects and financial health of Neurocrine Biosciences, and Neurocrine Biosciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Neurocrine Stock performance.
| Return On Equity | 0.14 | ||||
| Return On Asset | 0.1 | ||||
| Profit Margin | 0.14 % | ||||
| Operating Margin | 0.21 % | ||||
| Current Valuation | 10.54 B | ||||
| Shares Outstanding | 99.7 M | ||||
| Price To Earning | 202.90 X | ||||
| Price To Book | 4.31 X | ||||
| Price To Sales | 4.89 X | ||||
| Revenue | 2.36 B | ||||
| Gross Profit | 1.59 B | ||||
| EBITDA | 610.1 M | ||||
| Net Income | 341.3 M | ||||
| Cash And Equivalents | 799.4 M | ||||
| Cash Per Share | 8.31 X | ||||
| Total Debt | 455.1 M | ||||
| Debt To Equity | 0.18 % | ||||
| Current Ratio | 2.48 X | ||||
| Book Value Per Share | 26.05 X | ||||
| Cash Flow From Operations | 595.4 M | ||||
| Earnings Per Share | 3.29 X | ||||
| Market Capitalization | 11.53 B | ||||
| Total Asset | 3.72 B | ||||
| Retained Earnings | 29.2 M | ||||
| Working Capital | 1.22 B | ||||
| Current Asset | 384.07 M | ||||
| Current Liabilities | 25.71 M | ||||
About Neurocrine Biosciences Performance
Evaluating Neurocrine Biosciences' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Neurocrine Biosciences has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Neurocrine Biosciences has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 616.21 | 647.02 | |
| Return On Tangible Assets | 0.09 | 0.10 | |
| Return On Capital Employed | 0.18 | 0.19 | |
| Return On Assets | 0.09 | 0.10 | |
| Return On Equity | 0.13 | 0.14 |
Things to note about Neurocrine Biosciences performance evaluation
Checking the ongoing alerts about Neurocrine Biosciences for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Neurocrine Biosciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Neurocrine Biosciences generated a negative expected return over the last 90 days | |
| Neurocrine Biosciences has a strong financial position based on the latest SEC filings | |
| Over 98.0% of the company shares are owned by institutional investors | |
| Latest headline from gurufocus.com: Neurocrine Biosciences Inc Reports Promising 48-Week Remission Data for Tardive ... |
- Analyzing Neurocrine Biosciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Neurocrine Biosciences' stock is overvalued or undervalued compared to its peers.
- Examining Neurocrine Biosciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Neurocrine Biosciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Neurocrine Biosciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Neurocrine Biosciences' stock. These opinions can provide insight into Neurocrine Biosciences' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Neurocrine Stock Analysis
When running Neurocrine Biosciences' price analysis, check to measure Neurocrine Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neurocrine Biosciences is operating at the current time. Most of Neurocrine Biosciences' value examination focuses on studying past and present price action to predict the probability of Neurocrine Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neurocrine Biosciences' price. Additionally, you may evaluate how the addition of Neurocrine Biosciences to your portfolios can decrease your overall portfolio volatility.